<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223076</url>
  </required_header>
  <id_info>
    <org_study_id>2020/121314</org_study_id>
    <nct_id>NCT04223076</nct_id>
  </id_info>
  <brief_title>Clinical Effect of Chlorhexidine Mouthwash After Periodontal Surgery</brief_title>
  <official_title>Clinical Performance of Two 0.2% Chlorhexidine Mouth Rinses After Periodontal Surgery. A Blinded, Intra-individual Cross-over Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chlorhexidine is the gold standard of dental plaque prevention. Recent research have
      demonstrated that 0.2% Chlorhexidine solutions are more effective than 0.12% and 0.06%
      Chlorhexidine solutions. Several 0.2% solutions are available on the market. This study aimed
      to compare effectiveness of two commercially available 0.2% chlorhexidine mouthwashes.
      Patients, that after initial periodontal therapy, had a need for two periodontal surgeries,
      will be invited to join. After one surgical session, the patient will receive one 0.2%
      chlorhexidine solution, and after the next surgical session the patient will receive the
      other 0.2% chlorhexidine solution. Plaque and gingivitis will be recorded, as well as side
      effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Intra individual cross-over, double intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque index</measure>
    <time_frame>14 days intervention period</time_frame>
    <description>Dental Plaque</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gingival Index</measure>
    <time_frame>14 days intervention period</time_frame>
    <description>Gingivitis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Periodontal Diseases</condition>
  <condition>Periodontitis</condition>
  <condition>Dental Plaque</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine 0.2% mouthwash control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine 0.2%, Corsodyl Intervention rinsing 60 sec twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine 0.2% mouthwash with an Anti Discoloring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine 0.2%, Curasept Intervention rinsing 60 sec twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine 0.2%, Corsodyl</intervention_name>
    <description>Comparison of Corsodyl and Curasept</description>
    <arm_group_label>Chlorhexidine 0.2% mouthwash control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine 0.2%, Curasept</intervention_name>
    <description>Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)</description>
    <arm_group_label>Chlorhexidine 0.2% mouthwash with an Anti Discoloring System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Periodontitis, stage III and IV

        Exclusion Criteria:

        Uncontrolled diabetes Systemic conditions associated with excessive bleeding Uncontrolled
        hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Merete Aass, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Mauland, DDS</last_name>
    <phone>004747636914</phone>
    <email>erik.mauland@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Preus, Professor</last_name>
    <email>h.r.preus@odont.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erik Mauland</name>
      <address>
        <city>Oslo</city>
        <zip>0574</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Mauland</last_name>
      <phone>47636914</phone>
      <email>erik.mauland@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Erik Mauland</investigator_full_name>
    <investigator_title>DDS</investigator_title>
  </responsible_party>
  <keyword>Periodontal Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Dental Plaque</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

